-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Helus Pharma, Lowers Price Target to $70

Benzinga·07/09/2026 10:07:08
Listen to the news
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Helus Pharma (NASDAQ:HELP) with a Buy and lowers the price target from $95 to $70.